Immunovant, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ

20 May 2026

IMVT

10-K: Immunovant Shifts Focus to IMVT-1402 After Batoclimab Trial Setback

Immunovant Inc. reported its annual results, highlighting the discontinuation of batoclimab development to concentrate on IMVT-1402, while also detailing ongoing clinical trials and financial performance.

NASDAQ

29 May 2025

IMVT

Immunovant, INC

10-K: Immunovant Advances Best-in-Class FcRn Inhibitor IMVT-1402 with Multiple Registrational Trials Initiated and Strong Batoclimab Data Reported in Autoimmune Diseases

Immunovant, a clinical-stage immunology company, reported significant progress in its pipeline, initiating multiple registrational trials for its potentially best-in-class FcRn inhibitor IMVT-1402 across several autoimmune indications, while also announcing positive Phase 3 results for batoclimab in Myasthenia Gravis.

NASDAQ

29 May 2024

IMVT

Immunovant, INC

10-K: Immunovant's 10-K Filing: Focus on IMVT-1402 Development and Anti-FcRn Strategy

Immunovant's 10-K filing highlights the company's strategic shift towards IMVT-1402, a novel anti-FcRn antibody, while continuing development of batoclimab.